Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 1, 2011, Pages 165-174

  Muto, Chieko ^a,b   Liu, Ping ^a   Chiba, Koji ^b   Suwa, Toshio ^b  

^a PFIZER INC   (United States)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Azithromycin ER; Clinical efficacy; PK PD

Indexed keywords

AZITHROMYCIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL SINUSITIS; BRONCHITIS; CHRONIC RESPIRATORY TRACT DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED RELEASE FORMULATION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; ETHNIC DIFFERENCE; FEMALE; FIRST PASS EFFECT; HUMAN; JAPANESE; LARYNGOPHARYNGITIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PHARYNGITIS; RESPIRATORY TRACT INFECTION; TONSILLITIS; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; AZITHROMYCIN; BACTERIA; BACTERIAL INFECTIONS; DIARRHEA; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; SERUM; YOUNG ADULT;

EID: 78650393871     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq398     Document Type: Article

References (29)

1. Luke DR, Foulds G, Cohen SF et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996; 40: 2577-81.
2. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl A: 73-82.
3. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother 1993; 31 Suppl E: 39-50.
4. Liu P, Allaudeen H, Chandra R et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 2007; 51: 103-9.
5. Ehnhage A, Rautiainen M, Fang AF et al. Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis. Int J Antimicrob Agents 2008; 31: 561-6.
6. Lucchi M, Damle B, Fang A et al. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin. J Antimicrob Chemother 2008; 61: 884-91.
7. Chandra R, Liu P, Breen JD et al. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended release microsphere formulation of azithromycin. Clin Pharmacokinet 2007; 46: 247-59.
8. Girard D, Finegan SM, Dunne MW et al. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 2005; 56: 365-71.
9. Pfizer Inc. A Multicenter, Non-randomized, Open Label, Trial of Azithromycin SR for the Treatment of Mild to Moderate Community Acquired Pneumonia in Japanese Adults. The ClinicalStudyResultsorg Database: http://pdf.clinicalstudyresults.org/documents/company-study_4185_0.pdf (9 July 2010, date last accessed).
10. Pfizer Inc. A Multicenter, Non-randomized, Open Label Trial of Azithromycin SR for the Treatment of Acute Bronchitis and Secondary Infection of Chronic Respiratory Diseases in Japan Adults. The ClinicalStudyResultsorg Database: http://pdf.clinicalstudyresults.org/documents/company-study_4276_0.pdf (9 July 2010, date last accessed).
11. Pfizer Inc. A Multicenter, Non-randomized, Open label Trial of Azithromycin Sustained Release (SR) for the Treatment of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis in Japan Adults. The ClinicalStudyResultsorg Database: http://pdf.clinicalstudyresults.org/documents/company-study_4179_0.pdf (9 July 2010, date last accessed).
12. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
14. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria: Approved Guideline M45-A. CLSI, Wayne, PA, USA, 2006.
15. Beal SL, Sheiner LB. NONMEM Users Guides-Part I-VIII. University of California at San Francisco, San Francisco: NONMEM Project Group C255, 1988-98.
16. Gastonguay M. A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision. AAPS J 2004; 6 Suppl 1: 3431.
17. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007; 24: 2187-97.
18. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-32.
19. Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res 1999; 16: 709-17.
20. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20.
21. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21.
22. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008; 31: 12-20.
23. Culic O, Erakovic V, Cepelak I et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450: 277-89.
24. Ianaro A, Ialenti A, Maffia P et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-63.
25. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2007; 51: 975-81.
26. Koch CC, Esteban DJ, Chin AC et al. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J Antimicrob Chemother 2000; 46: 19-26.
27. Anderson R, Steel HC, Cockeran R et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 2007; 60: 1155-8.
28. Fukuda Y, Yanagihara K, Higashiyama Y et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 2006; 27: 1020-5.
29. Pfizer Inc. Zmax™ (Azithromycin Extended Release for Oral Suspension). New York, NY, 2008. http://www.pfizer.com/files/products/uspi_zmaxpdf (9 July 2010, date last accessed).